Emerging treatments
Temozolomide
Temozolomide, a second generation alkylating agent of the imidazotetrazine class, may be the only effective chemotherapeutic agent available for aggressive, progressive, and recurrent atypical pituitary adenomas and carcinomas resistant to conventional multi-modal treatment. However, it should be used with caution in view of the lack of controlled trials.[73] Compared with functioning pituitary tumours, clinically non-functional pituitary adenomas exhibit a lower response rate (45% vs 17%).[79]
Use of this content is subject to our disclaimer